Description

NUCOXIA 120 MG

Indications

NUCOXIA 120 MG, containing the active ingredient etoricoxib, is primarily indicated for the management of pain and inflammation associated with various conditions. These include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain. It is also indicated for the treatment of primary dysmenorrhea and for the management of gout flares. NUCOXIA is particularly beneficial for patients who require relief from pain without the gastrointestinal side effects commonly associated with traditional non-steroidal anti-inflammatory drugs (NSAIDs).

Mechanism of Action

NUCOXIA functions as a selective inhibitor of cyclooxygenase-2 (COX-2), an enzyme that plays a crucial role in the biosynthesis of prostaglandins. Prostaglandins are lipid compounds that mediate inflammation, pain, and fever. By selectively inhibiting COX-2, NUCOXIA reduces the production of these inflammatory mediators, thereby alleviating pain and inflammation while sparing the COX-1 enzyme, which is responsible for maintaining the protective lining of the gastrointestinal tract. This selective action helps minimize gastrointestinal side effects, making NUCOXIA a preferred option for long-term pain management.

Pharmacological Properties

NUCOXIA is rapidly absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 3 hours. The bioavailability of etoricoxib is approximately 100%, and it exhibits a linear pharmacokinetic profile within the therapeutic dose range. The drug is extensively metabolized in the liver, primarily via cytochrome P450 enzymes, particularly CYP2D6 and CYP3A4. The elimination half-life of etoricoxib is approximately 22 hours, allowing for once-daily dosing. It is primarily excreted in the urine as metabolites, with only a small percentage eliminated unchanged.

Contraindications

NUCOXIA is contraindicated in patients with a known hypersensitivity to etoricoxib or any of its components. It should not be used in individuals with a history of allergic reactions to other NSAIDs, including asthma, urticaria, or allergic-type reactions. Additionally, NUCOXIA is contraindicated in patients with severe hepatic impairment, active peptic ulcer disease, or gastrointestinal bleeding. It is also not recommended for use during pregnancy, especially in the third trimester, due to potential risks to the fetus.

Side Effects

The use of NUCOXIA may be associated with various side effects, although not all patients will experience them. Common side effects include headache, dizziness, gastrointestinal discomfort, and peripheral edema. Serious adverse effects may include cardiovascular events, such as myocardial infarction and stroke, particularly in patients with pre-existing cardiovascular conditions. Other serious side effects may involve renal impairment, liver function abnormalities, and hypersensitivity reactions. It is essential for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of NUCOXIA for adults varies depending on the specific condition being treated. For osteoarthritis and rheumatoid arthritis, the usual dose is 60 mg to 120 mg once daily. For ankylosing spondylitis, a dose of 90 mg once daily is typically recommended. In the case of acute pain or primary dysmenorrhea, a single dose of 120 mg may be administered. For gout flares, the recommended dose is 120 mg once daily for up to 8 days. It is important to follow the prescribing physician’s instructions and not exceed the recommended dosage to minimize the risk of adverse effects.

Interactions

NUCOXIA may interact with various medications, potentially altering their effects or increasing the risk of adverse reactions. Co-administration with other NSAIDs, anticoagulants, or antiplatelet agents may increase the risk of gastrointestinal bleeding. Additionally, etoricoxib may affect the metabolism of drugs that are substrates of CYP2D6 and CYP3A4, leading to altered plasma concentrations of these medications. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Patients using NUCOXIA should be monitored for signs of cardiovascular events, particularly those with pre-existing risk factors such as hypertension, hyperlipidemia, or diabetes. Caution should also be exercised in patients with a history of gastrointestinal disorders, renal impairment, or liver disease. It is advisable to use the lowest effective dose for the shortest duration necessary to manage symptoms. Regular follow-up appointments may be necessary to assess the patient’s response to treatment and monitor for any adverse effects.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of NUCOXIA in various patient populations. In a randomized controlled trial involving patients with osteoarthritis, NUCOXIA was shown to significantly reduce pain and improve function compared to placebo. Another study on patients with rheumatoid arthritis indicated that NUCOXIA effectively alleviated symptoms while maintaining a favorable safety profile. Long-term studies have also suggested that NUCOXIA may have a lower incidence of gastrointestinal complications compared to traditional NSAIDs, making it a valuable option for chronic pain management.

Conclusion

NUCOXIA 120 MG is a selective COX-2 inhibitor that provides effective relief from pain and inflammation associated with various musculoskeletal disorders. Its favorable pharmacokinetic profile, along with a reduced risk of gastrointestinal side effects, makes it a suitable choice for many patients. However, it is crucial for healthcare providers to assess individual patient risks and benefits before prescribing NUCOXIA. Continuous monitoring and patient education on the potential side effects and interactions are essential for ensuring safe and effective treatment.